Premier Alternatives

Claris Bio

Drug Discovery · Jersey City, NJ · Founded 2018 · Privately Held (backing)

Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. Claris Bio is based in Jersey City, NJ and was founded in 2018. It was valued at $163 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $54.5 million Series A in Jan 2024.

PMV mark · valuation
$163.4M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$153.6M
Last round
Later Stage VC (Series A)
Jan 2024

Claris Bio key facts

as of Oct 2026
  • Developer of a topical formulation technology designed to treat orphan ophthalmic disorders.
  • Claris Bio is valued at approximately $163.4M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $153.6M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($54.5M) in Jan 2024.
  • Notable investors include RA Capital Management, Novo Holdings, Catalio Capital Management, Janus Henderson Investors, Mass General Brigham Ventures.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$163.4M

Valued at $163.4M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Claris Bio with a free account
  • ·Watch Claris Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Claris Bio funding rounds

1 rounds
Jan 2024Later Stage VC (Series A)$54.5M▮
Full funding history →

Claris Bio valuation

Claris Bio was valued at $163 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Claris Bio raised?

Claris Bio has raised $154 million in total; 1 of its rounds is on record. The largest on record was a $54.5 million Series A in Jan 2024.

Claris Bio investors

5 investors are on record for Claris Bio, including RA Capital Management, Novo Holdings, Catalio Capital Management and Janus Henderson Investors. The Series A in Jan 2024 drew 3 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Cambrian Bio ($180 million), Gordian Biotechnology ($170 million) and Delix Therapeutics ($156 million).

About Claris Bio

Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. The company's technology creates a recombinant hepatocyte growth factor that accelerates the healing process, enabling healthcare professionals to get access to noninvasive treatment and patients to recover and stay fit.

Industry
Drug Discovery
Sector
Healthcare
HQ
Jersey City, NJ, United States
Founded
2018
Employees
5
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.